Last reviewed · How we verify
Sovaldi
Sovaldi is a Small molecule drug developed by Genuine Research Center, Egypt. It is currently FDA-approved for Chronic hepatitis C, Compensated cirrhosis, Decompensated cirrhosis of liver. Also known as: Sofosbuvir, GS-7977.
Sovaldi is a medication used to treat hepatitis C, taken by mouth. It works as a small molecule inhibitor of RNA-directed RNA polymerase, a specific enzyme involved in the replication of the hepatitis C virus.
At a glance
| Generic name | Sovaldi |
|---|---|
| Also known as | Sofosbuvir, GS-7977 |
| Sponsor | Genuine Research Center, Egypt |
| Target | Cereblon isoform 4, Genome polyprotein, NS5 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Chronic hepatitis C
- Compensated cirrhosis
- Decompensated cirrhosis of liver
Common side effects
- Fatigue
- Headache
- Nausea
- Insomnia
- Anemia
Serious adverse events
- Pancytopenia
- Severe depression
- Suicidal ideation
- Suicide
- Bilirubin elevation (>2.5×ULN)
- Creatine kinase elevation (≥10×ULN)
- Lipase elevation (>3×ULN)
- Neutropenia
Key clinical trials
- People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents (PHASE4)
- A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients (PHASE2)
- Implementing Low-Barrier HCV Treatment in a Jail Setting (PHASE4)
- Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients (NA)
- Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy (PHASE4)
- Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients (PHASE2)
- C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV (PHASE3)
- SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sovaldi CI brief — competitive landscape report
- Sovaldi updates RSS · CI watch RSS
- Genuine Research Center, Egypt portfolio CI
Frequently asked questions about Sovaldi
What is Sovaldi?
What is Sovaldi used for?
Who makes Sovaldi?
Is Sovaldi also known as anything else?
What development phase is Sovaldi in?
What are the side effects of Sovaldi?
What does Sovaldi target?
Related
- Target: All drugs targeting Cereblon isoform 4, Genome polyprotein, NS5
- Manufacturer: Genuine Research Center, Egypt — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Chronic hepatitis C
- Indication: Drugs for Compensated cirrhosis
- Indication: Drugs for Decompensated cirrhosis of liver
- Also known as: Sofosbuvir, GS-7977
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing